Amgen Granted FDA Priority Review for Expanded Use of Kyprolis

Amgen Inc. said the U.S. Food and Drug Administration granted priority review status to its supplemental new drug application for Kyprolis to treat patients with relapsed multiple myeloma who have received at least one prior therapy.



from WSJ.com: US Business http://ift.tt/1ErACJP

via IFTTT